Humira, Rituxan top list of U.S. drugs with biggest price increases -report

AbbVie Inc's arthritis drug Humira and Roche Holding AG's cancer drug Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed.